Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News B Braun reports positive data from SeQuent Please trial

B Braun reports positive data from SeQuent Please trial

10th September 2012

B Braun has highlighted data from a clinical trial showing the advantages its drug-eluting balloon SeQuent Please can offer in comparison to other similar products.

A report from the Swedish SCAAR registry has been published by Dr Per Bondesson and colleagues from Lund University in the journal Eurointerventions, which revealed analysing consecutive patient data from all 29 coronary angioplasty performing centres across the nation.

It was found that not all drug-eluting balloons used in these procedures were equally effective, with B Braun's SeQuent Please delivering an overall incidence of restenosis at six months of 3.4 percent, compared to 12.5 percent with a different device.

Based on this evidence, SeQuent Please can be considered a reasonable alternative to drug-eluting stents for selected patients with coronary artery disease.

The company said: "It is the most advanced solution for the treatment of patients with in-stent restenosis and it represents currently the most promising therapeutic alternative to reduce the number of unnecessary stent implantations."

Earlier this year, B Braun won an Investors in People Gold Award, thanks to the high standards of its people management in the UK.ADNFCR-8000103-ID-801445871-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.